1. Introduction {#sec1}
===============

Naoxintong capsule (NXT) is a commercial medicinal product approved by the China Food and Drug Administration which is widely used in the treatment of stroke and coronary heart disease. NXT contains 16 Chinese herbal medicines ([Table 1](#tab1){ref-type="table"}). NXT exerts significant therapeutic effects and has high safety for stroke recovery in the clinical setting \[[@B1]\]. Recent studies showed that NXT could reduce the infarct size of acute myocardial infarction (AMI) patients by improving vascular endothelial function \[[@B2]\]. Long-term administration of NXT was also reported to alleviate inflammation, reduce the recurrence of angina pectoris, and decrease the incidence of ACS attack in borderline lesion coronary heart disease patients \[[@B3]\]. Some studies investigated the mechanisms of NXT in vitro or in vivo. NXT was reported to protect against atherosclerosis through its lipid-lowering activity \[[@B4]\] and to reduce the expression of iNOS mRNA and the NO level in the vessel wall to benefit the treatment of atherosclerosis \[[@B5]\]. NXT also protected cardiomyoblasts against H~2~O~2~-induced oxidative injury \[[@B6]\]. Although some mechanisms of NXT have been reported, existing studies on unilateral factors and single targets could not demonstrate the complex mechanisms of NXT, a herbal prescription with 16 medicines which is prescribed for the treatment of complex diseases like cardiovascular and cerebrovascular diseases.

With the prominence of network pharmacology in system biology, this distinct and novel approach to the study of complicated analytical systems is becoming more widely known and more frequently used in the field of drug research. The functions of network pharmacology include uncovering the functions of traditional Chinese medicines (TCMs), providing deeper insights into and scientific evidence for TCMs, and identifying TCMs as scientifically proven. Here, we attempt to explore the mechanism of NXT using this method.

In the current study, based on the use of UPLC/Q-TOF-MS to investigate the involved components, we aimed to analyse the absorbable components of NXT, to identify potential targets and associated pathways using the network pharmacology method, and to systematically discuss the mechanism of NXT in the treatment of heart diseases.

2. Material and Methods {#sec2}
=======================

2.1. Prediction of Components {#sec2.1}
-----------------------------

### 2.1.1. Sample Preparation {#sec2.1.1}

NXT was obtained from HezeBuchang Pharmaceutical Co., Ltd. (Heze, China). Deionized water was prepared from aqua distillate using a Milli-Q system (Millipore, Bedford, MA, USA). Analytical grade methanol was purchased from Merck (Darmstadt, Germany). We dissolved 1 g of NXT powder in 10 mL of 75% analytical grade methanol and subjected the mixture to ultrasonic extraction for 30 min. We then brought the solution to room temperature and obtained the supernatant as a capture reagent. The sample was filtered using a 0.22 *μ*m microporous membrane before UPLC analysis.

### 2.1.2. UPLC/Q-TOF-MS {#sec2.1.2}

We used a Waters Acquity UPLC System (Waters Co., USA) furnished with a photodiode array detector for the analysis. The sample was diluted on a Waters Acquity UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 *μ*m). UV detection was achieved at 190--400 nm. The system was controlled using the MassLynx version 4.1 software (Waters Co.). The gradient duration program for A (UPLC-grade acetonitrile) and B (water with 0.1% formic acid) was performed as follows: 2% A from 0 min to 3 min, 10% to 50% A from 3 min to 12 min, 50% to 63% A from 12 min to 18 min, 63% to 83% A from 18 min to 21 min, 83% to 84% A from 21 min to 22 min, 84% to 87% A from 22 min to 26 min, 87% to 90% A from 26 min to 28 min, 90% to 95% A from 28 min to 31 min, 95% to 100% A from 31 to 33 min, 100% to 100% A from 33 to 35 min, and 100% to 2% A from 35 min to 37 min. The flow rate was maintained at 0.4 mL/min, and the column temperature was maintained at 30°C.

The components of NXT were identified using a Waters Q-TOF Premier with an electrospray ionization (ESI) system (Waters MS Technologies, Manchester, UK). The ESI-MS spectra were acquired at both negative and positive ion voltages. The capillary voltage was set to 2.5 kV for the negative mode and to 3.0 kV for the positive mode. The sample cone voltage was set to 30 V, and the source temperature was 110°C. High-purity nitrogen was used as the nebulization and auxiliary gas. The nebulization gas was set to 600 L/h, the cone gas was set to 50 L/h, and the desolation temperature was 350°C. The Q-TOF Premier acquisition rate was 0.1 s, and there was a 0.02 s interscan delay. Argon, which was used as the collision gas, was maintained at a pressure of 5.3 × 10^−5^ Torr. The instrument was operated with the first resolving quadruple in a wide pass mode (100 Da--1500 Da). Leucineen kephalinamide acetate was used as the lock mass (\[M − H\]^−^ = 553.2775, \[M + H\]^+^ = 555.2931).

2.2. Calculation and Prediction of Absorbable Components {#sec2.2}
--------------------------------------------------------

First, we determined the structural formulas of the chemical components that were identified in compound NXT from the Chemical Book website and used the Chemdraw software to draw these formulas. Then, we imported these structural formulas into the Online SMILES Translator and Structure File Generator (<http://cactus.nci.nih.gov/translate/>) to obtain the smiles format. Finally, we input the smiles format of the chemical components into the Molispiration Smiles website (<http://www.molinspiration.com/cgi-bin/properties>) to calculate the prediction parameters of drug absorption. According to the five principles of drug absorption, if a component was subject to the following provisions of the corresponding parameters, it could be identified as an absorbable component: hydrogen bond donor (the number of hydrogen atoms attached to the O and N) *n*OHNH ≤ 5; relative molecular mass MW ≤ 500; fat water partition coefficient miLog*P* ≤ 5; and hydrogen bond acceptor (the number of O and N) *n*ON ≤ 10.

2.3. Prediction and Screening of Targets {#sec2.3}
----------------------------------------

Using the software of Chembio3D Ultru12.0, we transformed the structure of the absorbed components into the sdf structure format. Then, to predict the possible targets, we imported the components into the public network server of the target database of the efficacy group PharmaMapper website (<http://59.78.96.61/pharmmapper/>) to perform reverse docking. We selected the top 10 targets for subsequent study.

2.4. Prediction and Screening of Pathways {#sec2.4}
-----------------------------------------

We imported the obtained targets into the Bio database (<http://bioinfo.capitalbio.com/mas3/>) and then screened for pathways that met the criterion of *P* \< 0.01.

2.5. Construction of Network {#sec2.5}
----------------------------

According to the screening pathways with their corresponding targets and components, we created a component-target-pathway illustration using Cytoscape. Then, according to the main selected targets, we drew a target-composition diagram.

3. Results {#sec3}
==========

3.1. UPLC/Q-TOF-MS Analysis {#sec3.1}
---------------------------

We analysed the chemical components of NXT using ultraperformance liquid chromatography combined with quadrupole time-of-flight mass spectrometry. Because different chemical components had better responses in different modes, MS data were obtained in both positive ion mode ([Figure 1(a)](#fig1){ref-type="fig"}) and negative ion mode ([Figure 1(b)](#fig1){ref-type="fig"}). MS data in (+/−) ESI modes and the identification results for the constituents in NXT were presented in [Table 2](#tab2){ref-type="table"}. In all 16 herbs from NXT, no related component in Myrrha and Hirudo was found.

3.2. Absorption Parameters of Components {#sec3.2}
----------------------------------------

Using a computer prediction method to calculate the identified compounds of NXT, we obtained absorption parameters that could determine whether the chemical compositions could be absorbed. [Table 3](#tab3){ref-type="table"} showed the specific absorption parameters of all of the components. The data indicated that there were a total of 63 chemical compositions ([Figure 2](#fig2){ref-type="fig"}) that met the five principles of drug absorption. As shown, 7 glycosides were identified. Although the relative molecular masses of those compounds were greater than 500, they could also be absorbed, because those compounds could be divided into two parts, including aglycones which mainly mediated drug efficacy and sugar chains in the body. So we could import these glycosides\' aglycones into PharmMapper to obtain the relevant parameters. The results showed that both of these components were consistent with the five principles of drug absorption, so we considered that these 7 chemical compositions could be absorbed in the body.

3.3. Potential Targets and Pathways {#sec3.3}
-----------------------------------

By importing 63 chemical compositions that were predicted to be absorbable into the PharmMapper database for directional docking, we obtained a total of 123 targets. We then imported these targets into the Molecule Annotation System and obtained 77 pathways regulated by NXT with highly significant differences, from which we chose the top 40 pathways that met the criterion of *P* \< 0.01 ([Table 4](#tab4){ref-type="table"}). A total of 34 targets were related to these top 40 pathways, and HRAS, MAP2K1, and MAPK14 were associated with most of these pathways, so we considered these factors to be the main targets. As shown in [Table 4](#tab4){ref-type="table"}, NFAT and hypertrophy of the heart (transcription in the broken heart) ranked first among these pathways.

In [Table 5](#tab5){ref-type="table"}, these top 40 pathways were classified into 5 categories, which included pathways associated with heart diseases and blood vessels, metabolism, cell cycle (with proliferation and apoptosis), immunity, and other pathways. By classifying these pathways, we accessed and marked the corresponding medicinal materials of NXT ([Table 5](#tab5){ref-type="table"}). In the pathways associated with heart diseases and blood vessels, RCX, RSM, and FC were the most important. In the regulation of metabolism, RA, RSM, and RCX showed diametrical effect. All the herbs except Semen Persicae (SP) were related metabolism pathways due to the current research. RA, RSM, RCX, and FC could regulate the pathways about cell cycle, proliferation, and apoptosis. Some other important pathways were also affected by some herbs like RA, RSM, and RCX, for example, Insulin Signaling Pathway and p38 MAPK Signaling Pathway.

3.4. Pharmacology Network of NXT {#sec3.4}
--------------------------------

Using the Cytoscape software, we constructed a pharmacology network of NXT ([Figure 3](#fig3){ref-type="fig"}), which showed us the relationships of the top 40 pathways, targets, and chemical components. We obtained preliminary understanding of the mechanism of NXT through this network.

In this research, we found three major targets of NXT: HRAS, MAP2K1, and MAPK14, which were involved in most regulated pathways. By [Figure 4](#fig4){ref-type="fig"}, based on illustration of the main targets with their corresponding compounds, we found the most effective ingredients of NXT were organic acids, saponins, and tanshinones. The main sources of organic acids were RA, RCX, RAS, and RAB. The saponins were mainly derived from RA. Meanwhile, tanshinones were mainly concentrated in RSM.

4. Discussion {#sec4}
=============

The burden of cardiovascular and circulatory disease is becoming more and more serious, with cerebrovascular disease (CBD) and ischemic heart disease being the most serious \[[@B7]\]. As the causes of cardiovascular disease (CVD) and CBD are complicated, the symptoms of these diseases are also very diverse. NXT is commonly used during clinical treatment of CVD and CBD, and the effect of this drug is remarkable. Although complex traditional Chinese medicine has great significance for the treatment of complex diseases, some questions such as the material basis and the potential mechanisms remain unanswered.

Our study successfully predicted absorbable chemical compositions of NXT. These constituents primarily included ferulic acid, succinic acid, astragaloside IV, and tanshinone IIA. Ferulic acid, which is derived primarily from RA, RCX, RAS, and RAB, is reported to act as an angiogenic agent that augments angiogenesis, which is critical in ischemic diseases, such as myocardial infarction and stroke \[[@B8]\]. Succinic acid has been demonstrated to activate Akt phosphorylation to inhibit apoptosis and necrosis caused by cardiomyocyte hypoxia/reoxygenation \[[@B9]\]. Previous studies demonstrated that astragaloside IV could protect the heart through NO-dependent mechanism \[[@B10]\]. NO has been confirmed to prevent the mitochondrial permeability transition pore from opening \[[@B11]\]. During early reperfusion, it can prevent the heart from reperfusion injury by inhibiting the opening of the mitochondrial permeability transition pore \[[@B12]\]. Tanshinone IIA also has cardioprotective effects, such as protection of cardiomyocytes from oxidative stress-triggered damage \[[@B13]\]. These reports were consistent with our results.

In addition to active ingredients, we also successfully predicted drug targets of NXT. The major targets were HRAS, MAP2K1, and MAPK14. The HRAS gene encodes the GTPase HRas, which is an enzyme known as transforming protein p21 \[[@B14]\]. With the ability to increase the effects of growth factor, HRas plays an important role in regulating the growth, differentiation, and death of endothelial cells \[[@B15]\]. The MAP2K1 gene encodes an enzyme named dual specificity mitogen-activated protein kinase kinase 1, and MAPK14 encodes p38-*α*. Both of these factors are closely related to inflammation and p38-*α* is also associated with cardiac hypertrophy via p38 MAPK activity in the heart. In addition, p38-*α* has been recognized as an isoenzyme of cardiovascular importance \[[@B16]\].

Among the numerous identified pathways, NFAT and hypertrophy of the heart (transcription in the broken heart) were ranked first. Nuclear factor of activated T-cells (NFAT) transcription factors, which have four different isoforms, plays crucial roles in the regulation of gene expression during heart development \[[@B17]\]. The isoforms NFATc3 and NFATc4 are involved in hypertrophic development, while NFATc1 plays a key role in cardiac development \[[@B18]\]. The dephosphorylation of NFATs can promote calcineurin regulating immune response genes \[[@B19]\]. Via compensatory hypertrophy, the heart adapts to persistent stress conditions, but, over time, dysfunction and myocardial failure evolve \[[@B20]\]. Like NFAT and hypertrophy of the heart (transcription in the broken heart), most of these pathways are involved in the formation and regulation of cardiovascular disease, such as nuclear receptors in lipid metabolism and toxicity. Nuclear receptors include a superfamily of ligand-dependent transcription factors that regulate genetic networks that control cell growth, development, and metabolism. Regulating nuclear receptors is beneficial for patients with metabolic diseases, such as cardiovascular disease, due to the requirement for balance among a number of pathways for normal metabolic control \[[@B21]\]. These studies confirmed the validity of our study.

From the above results, we also found the different significances of the total of 16 herbs in NXT. According to Chinese Pharmacopoeia 2015, the content of RA in NXT is 66 g, which is 2-3 times the content of any other herb in the whole prescription. It was reported that RA was the monarch drug of NXT and played a key role in improving the immune system, invigorating blood circulation, and the condition of myocardial ischemia and hypoxia \[[@B22]\]. Our study found that RA contained a lot of effective components, organic acids, and saponins and was critical source of the main active components of NXT. Through the comparison of the herbs involved in the top 40 pathways, RA was also proved to be the most important. In the top 40 pathways regulated by NXT, RA was involved in 33 pathways. Some other herbs, such as RSM, RCX, FC, and RAS, were also the important contents in the whole prescription of NXT.

The network pharmacology method used in this study is a novel methodology based on the construction of multilayer networks of disease phenotype-gene-drug to predict drug targets in a holistic manner and promote efficient drug discovery \[[@B23]\]. This method represents a breakthrough in comparison to the traditional herbal medicine research pattern "gene-target-disease" and initiates the new pattern "multiple genes-multiple targets-complex diseases" \[[@B24]\]. By this method, we proved that RA was the critical ingredient mainly involved in the regulation of metabolism and immunity in NXT. RAS was a major herb that regulated cell growth. RSM, RCX, and FC also played important roles in regulation of heart disease, blood vessels, and others. The results indicated that NXT, a complex prescription in the treatment of complex diseases, played a therapeutic effect through multiple targets and multiple pathways. This was the first study to investigate the mechanism of NXT using this method, and we successfully predicted the main targets and pathways, providing a foundation for further research. This method has important value for the study of complex drugs and should be applied in future studies.

5. Conclusion {#sec5}
=============

The main components that mediated the efficacy of NXT were organic acids, saponins, and tanshinones. Radix Astragali was the critical herbal medicine in NXT, which contained more active components than others and regulated more targets and pathways. NXT had a therapeutic effect on the treatment of heart diseases through the pattern "multiple components-multiple targets-multiple pathways."
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![UPLC/Q-TOF-MS analysis of NXT. (a) Chromatograms of NXT in positive ion mode. (b) Chromatograms of NXT in negative ion mode.](ECAM2016-9468087.001){#fig1}
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###### 

Sixteen Chinese traditional medical herbs of NXT.

  Abbreviation   Medicinal herbs                Original plants                                                                                                                                Content (g)^*∗*^
  -------------- ------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  RA             Radix Astragali                *Astragalus membranaceus*(Fisch.) Beg. var. *mongholicus* (Bge.) Hsiao or *A. membranaceus* (Fisch.) Bge.                                      66
  RPR            Radix Paeoniae Rubra           *Paeonia lactiflora*Pall. or *P. veitchii*Lynch                                                                                                27
  RSM            Radix Salviae Miltiorrhizae    *Salvia miltiorrhiza*Bge.                                                                                                                      27
  RAS            Radix Angelicae Sinensis       *Angelica sinensis (Oliv) Diels.*                                                                                                              27
  RCX            Rhizoma Chuanxiong             *Ligusticum chuanxiong*Hort.                                                                                                                   27
  SP             Semen Persicae                 *Prunus persica* (L.) Batsch or *Prunusdavidiana* (Carr.) Franch.                                                                              27
  FC             Flos Carthami                  *Carthamus tinctorius* L.                                                                                                                      13
  FK             Frankincense                   *Boswellia carterii Birdw.*                                                                                                                    13
  MRH            Myrrha                         *Commiphora myrrha*Engl.                                                                                                                       13
  CS             Caulis Spatholobi              *Spatholobus suberectus*Dunn                                                                                                                   20
  RAB            Radix Achyranthis Bidentatae   *Achyranthes bidentata* Bl. or *Cyathula officinalis* Kuan                                                                                     27
  RC             Ramulus Cinnamomi              *Cinnamomum cassia* Presl                                                                                                                      20
  RM             Ramulus Mori                   *Morus alba* L.                                                                                                                                27
  PT             Pheretima                      *Pheretima aspergillum*(E. Perrier) or *Pheretima vulgaris* Chen. or*Pheretima guillelmi* (Michaelsen) or *Pheretima pectinifera* Michaelsen   27
  SCP            Scorpio                        *Buthus martensii* Karsch                                                                                                                      13
  HRD            Hirudo                         *Whitmania pigra* Whitman or *Hirudo nipponica* Whitman or *Whitmania acranulata* Whitman                                                      27

^*∗*^ *Note*. The content of 16 Chinese traditional medical herbs of NXT came from Chinese Pharmacopoeia 2015.

###### 

MS data in (+/−) ESI modes and the identification results for the constituents in NXT.

  Peak number   RT (min)   Identification                                    Mode      MS (*m*/*z*)   Composition          Herbal source
  ------------- ---------- ------------------------------------------------- --------- -------------- -------------------- -------------------
  1             0.647      Arginine                                          Pos/Neg   174.2024       C~6~H~14~N~4~O~2~    PT
  2             0.702      Valine                                            Pos       117.1478       C~5~H~11~NO~2~       PT
  3             0.721      Proline                                           Pos       115.1331       C~5~H~9~NO~2~        PT
  4             0.776      Malic acid                                        Neg       134.0911       C~4~H~6~O~5~         RA
  5             1.053      Citric acid                                       Neg       192.1286       C~6~H~8~O~7~         RA
  6             1.201      D-5-oxoproline                                    Neg       129.1174       C~5~H~7~NO~3~        RAS
  7             1.201      L-5-oxoproline                                    Neg       129.1174       C~5~H~7~NO~3~        RAS
  8             1.275      Succinic acid                                     Neg       118.0910       C~4~H~6~O~4~         RAS, RAB, PT
  9             1.294      *ρ*-Coumaric acid                                 Pos       164.1601       C~9~H~8~O~3~         RAS
  10            1.310      o-Phthalic acid                                   Pos       166.1294       C~8~H~6~O~4~         RAS
  11            1.312      Adenosine                                         Pos       267.2403       C~10~H~13~N~5~O~4~   RAS, PT, RCX
  12            1.331      Leucine                                           Pos       131.1688       C~6~H~13~NO~2~       PT
  13            1.460      Isoleucine                                        Pos       131.1688       C~6~H~13~NO~2~       RAB
  14            1.589      Gallic acid^a^                                    Neg       170.1207       C~7~H~6~O~5~         RPR
  15            2.199      Phenylalanine                                     Pos       165.1874       C~9~H~11~NO~2~       FC
  16            2.459      Danshensu                                         Neg       198.1701       C~9~H~10~O~5~        RSM
  17            2.606      Palmitic acid                                     Neg       256.3380       C~16~H~32~O~2~       RAS, FC, RA, SCP
  18            3.438      Senkyunolide B                                    Neg       204.2374       C~12~H~12~O~3~       RCX
  19            3.456      Senkyunolide C                                    Neg       204.2374       C~12~H~12~O~3~       RCX
  20            3.600      Protocatechuic aldehyde                           Neg       138.1185       C~7~H~6~O~3~         RSM, RC
  21            3.974      Mulberroside A^a^                                 Neg       568.5277       C~26~H~32~O~14~      RM
  22            4.122      Gallicin                                          Neg       184.1453       C~8~H~8~O~5~         RPR
  23            4.230      Hydroxysafflor yellow A                           Pos/Neg   612.5364       C~27~H~32~O~16~      FC
  24            4.232      7-Hydroxycoumarin                                 Pos       162.1457       C~9~H~6~O~3~         RM
  25            4.565      Vanillic acid                                     Neg       168.1459       C~8~H~8~O~4~         RCX, RPR
  26            4.694      Benzoic acid                                      Neg       122.1209       C~7~H~6~O~2~         RPR
  27            4.935      Epicatechin                                       Neg       290.2674       C~15~H~14~O~6~       CS
  28            5.157      Catechin                                          Neg       290.2674       C~15~H~14~O~6~       RPR
  29            5.212      Albiflorin                                        Pos       480.4653       C~23~H~28~O~11~      RPR
  30            5.730      Quercetin-7-O-glucoside                           Neg       464.3754       C~21~H~20~O~12~      FC
  31            5.952      Rutin                                             Neg       610.5203       C~27~H~30~O~16~      RA
  32            5.970      Calycosin^a^                                      Neg       284.2679       C~16~H~12~O~5~       RA
  33            5.988      Calycosin-7-O-glucoside                           Pos       446.4075       C~22~H~22~O~10~      RA
  34            5.989      Ferulic acid^a^                                   Neg       194.1815       C~10~H~10~O~4~       RA, RCX, RAS, RAB
  35            6.321      Paeoniflorin^a^                                   Pos       480.466        C~23~H~28~O~11~      RPR
  36            6.358      Pentagalloylglucose^a^                            Neg       940.68         C~41~H~32~O~26~      RPR
  37            6.413      Kaempferol-3-O-rutinoside^a^                      Pos/Neg   594.5179       C~27~H~30~O~15~      FC
  38            6.654      3,5-Di-O-caffeoylquinic acid^a^                   Pos/Neg   516.4573       C~25~H~24~O~12~      CS
  39            6.987      Dicaffeoylquinic acid                             Neg       516.1275       C~25~H~24~O~12~      RCX
  40            7.042      Z-Butylidenephthalide^a^                          Neg       188.2259       C~12~H~12~O~2~       RCX
  41            7.210      Salvianolic acid A                                Neg       494.4578       C~26~H~22~O~10~      RSM
  42            7.449      4-Hydroxyl-3-butylphthalide                       Pos       206.2346       C~12~H~14~O~3~       RCX
  43            7.540      Salvianolic acid B                                Neg       718.6220       C~36~H~30~O~16~      RSM
  44            7.688      Ononin                                            Pos       430.4107       C~22~H~22~O~9~       CS
  45            7.763      Senkyunolide F                                    Pos       206.1017       C~12~H~14~O~3~       RCX, RAS
  46            7.855      Salvianolic acid E                                Neg       718.1512       C~36~H~30~O~16~      RSM
  47            8.243      Biochanin A                                       Pos/Neg   284.2689       C~16~H~12~O~5~       CS
  48            8.262      (6aR,11aR)-3-Hydroxy-9,10-dimethoxy pterocarpan   Pos       300.3107       C~17~H~16~O~5~       RA
  49            8.594      N1-N5-(Z)-N10-(E)-tri-p-coumaroylspermidine       Pos       583.2703       C~34~H~37~N~3~O~6~   FC
  50            8.740      Benzoylpaeoniflorin                               Pos       584.5723       C~30~H~32~O~12~      RPR
  51            9.518      Pratensein                                        Neg       300.0679       C~16~H~12~O~6~       RA
  52            9.611      Hydroxyl calendic acid                            Neg       294.4342       C~18~H~30~O~3~       SP
  53            9.648      *Trans*-oxyresveratrol                            Pos       244.2435       C~14~H~12~O~4~       RM
  54            10.240     Formononetin^a^                                   Pos/Neg   268.2580       C~16~H~12~O~4~       RA
  55            10.405     Astragaloside IV                                  Neg       784.4633       C~41~H~68~O~14~      RA
  56            10.590     Senkyunolide H                                    Neg       220.2305       C~12~H~12~O~4~       RCX
  57            10.978     Astragaloside II                                  Neg       826.4701       C~43~H~70~O~15~      RA
  58            11.311     Soyasaponin I                                     Neg       942.5145       C~48~H~78~O~18~      RA
  59            11.422     Methyl tanshinonate                               Pos       338.1087       C~20~H~18~O~5~       RSM
  60            11.588     Carnosic acid                                     Neg       332.4311       C~20~H~28~O~4~       RSM
  61            11.644     Kaempferol-3-O-glucoside                          Neg       448.3752       C~21~H~20~O~11~      FC
  62            11.699     Hydroxytanshinone IIA                             Pos       310.1199       C~19~H~18~O~4~       RSM
  63            11.792     3-Butylidene-7-hydroxyphalide                     Neg       204.2331       C~12~H~12~O~3~       RCX
  64            11.921     Tanshinone II-B                                   Pos       310.1187       C~19~H~18~O~4~       RSM
  65            12.198     Senkyunolide A                                    Pos       192.2516       C~12~H~16~O~2~       RCX
  66            12.975     Salvianolic acid F                                Neg       314.0735       C~17~H~14~O~6~       RSM
  67            13.196     Kumatakenin                                       Neg       314.3359       C~17~H~14~O~6~       RA
  68            13.233     3-n-Butylphthalide                                Pos       190.2356       C~12~H~14~O~2~       RCX
  69            13.474     (Z)-ligustilide^a^                                Pos       190.2109       C~12~H~14~O~2~       RAS
  70            13.483     (E)-ligustilide^a^                                Pos       190.2109       C~12~H~14~O~2~       RAS
  71            13.917     Trijuganone B                                     Pos       280.1107       C~18~H~16~O~3~       RSM
  72            16.098     Cryptotanshinone^a^                               Neg       296.3642       C~19~H~20~O~3~       RSM
  73            16.394     Senkyunolide M                                    Pos       278.1565       C~16~H~22~O~4~       RCX
  74            17.503     O-Phthalic anhydride                              Pos       148.0207       C~8~H~4~O~3~         FC
  75            17.614     Chlorogenic acid^a^                               Neg       354.3120       C~16~H~18~O~9~       CS
  76            18.076     Tanshinone IIA                                    Pos       294.3430       C~19~H~18~O~3~       RSM
  77            18.205     Angelicide                                        Pos       380.1917       C~24~H~28~O~4~       RCX
  78            20.460     Carthamidin                                       Pos       288.2575       C~15~H~12~O~6~       FC
  79            22.078     Linoleic acid                                     Neg       280.2387       C~18~H~32~O~2~       SP
  80            22.659     Acetyl-11-keto-*β*-boswellic acid                 Pos/Neg   512.7458       C~32~H~48~O~5~       FK
  81            22.881     Oleanolic acid                                    Neg       456.3652       C~30~H~48~O~3~       RSM

"a" refers to the component has been verified by standard substance.

###### 

Absorption parameters of the components.

  Number   Compounds                                         MW        *n*ON   *n*OHNH   miLog*P*   Results
  -------- ------------------------------------------------- --------- ------- --------- ---------- ---------
  1        Arginine                                          174.204   6       7         −3.632     *✕*
  2        Valine                                            117.15    3       3         −1.91      √
  3        Proline                                           115.132   3       2         −1.723     √
  4        Malic acid                                        134.087   5       3         −1.57      √
  5        Citric acid                                       192.123   7       4         −1.983     √
  6        D-5-oxoproline                                    129.115   4       2         −2.402     √
  7        L-5-oxoproline                                    129.115   4       2         −2.402     √
  8        Succinic acid                                     118.088   4       2         −0.655     √
  9        *ρ*-Coumaric acid                                 164.160   3       2         1.43       √
  10       o-Phthalic acid                                   166.132   4       2         1.034      √
  11       Adenosine                                         267.245   9       5         −0.854     √
  12       Leucine                                           131.175   3       3         −1.382     √
  13       Isoleucine                                        131.175   3       3         −1.41      √
  14       Gallic acid^a^                                    170.120   5       4         0.589      √
  15       Phenylalanine                                     165.192   3       3         −1.231     √
  16       Danshensu                                         198.174   5       4         −0.251     √
  17       Palmitic acid                                     256.43    2       1         7.059      *✕*
  18       Senkyunolide B                                    204.225   3       1         2.81       √
  19       Senkyunolide C                                    204.225   3       1         2.574      √
  20       Protocatechuic aldehyde                           138.122   3       2         0.759      √
  21       Mulberroside A^a^                                 568.528   14      10        −0.852     √
  22       Gallicin                                          184.147   5       3         0.848      √
  23       Hydroxysafflor yellow A                           612.54    16      12        −4.12      √
  24       7-Hydroxycoumarin                                 162.144   3       1         1.511      √
  25       Vanillic acid                                     168.148   4       2         1.187      √
  26       Benzoic acid                                      122.123   2       1         1.848      √
  27       Epicatechin                                       290.271   6       5         1.369      √
  28       Catechin                                          290.271   6       5         1.369      √
  29       Albiflorin                                        480.466   11      5         −1.636     *✕*
  30       Quercetin-7-O-glucoside                           464.379   12      8         −0.104     *✕*
  31       Rutin                                             610.521   16      10        −1.063     √
  32       Calycosin^a^                                      284.267   5       2         2.377      √
  33       Calycosin-7-O-glucoside                           446.408   10      5         0.59       √
  34       Ferulic acid^a^                                   194.186   4       2         1.249      √
  35       Paeoniflorin^a^                                   480.466   11      5         0.044      *✕*
  36       Pentagalloylglucose^a^                            940.681   26      15        2.761      √
  37       Kaempferol-3-O-rutinoside^a^                      594.522   15      9         −0.574     √
  38       3,5-Di-O-caffeoylquinic acid^a^                   516.455   12      7         1.424      *✕*
  39       Dicaffeoylquinic acid                             516.46    12      7         1.21       *✕*
  40       Z-Butylidenephthalide^a^                          188.226   2       0         3.077      √
  41       Salvianolic acid A                                494.452   10      7         3.014      *✕*
  42       4-Hydroxyl-3-butylphthalide                       206.241   3       1         3.42       √
  43       Salvianolic acid B                                718.620   16      9         1.615      *✕*
  44       Ononin                                            430.409   9       4         1.307      √
  45       Senkyunolide F                                    206.24    3       1         1.72       √
  46       Salvianolic acid E                                718.62    16      10        2.83       *✕*
  47       Biochanin A                                       284.267   5       2         2.804      √
  48       (6aR,11aR)-3-Hydroxy-9,10-dimethoxy pterocarpan   300.31    5       1         2.546      √
  49       N1-N5-(Z)-N10-(E)-tri-p-coumaroylspermidine       538.68    9       5         4.3        *✕*
  50       Benzoylpaeoniflorin                               584.574   12      4         2.472      *✕*
  51       Pratensein                                        300.27    6       3         2.09       √
  52       Hydroxyl calendic acid                            294.435   3       2         4.93       √
  53       Trans-Oxyresveratrol                              244.246   4       4         2.723      √
  54       Formononetin^a^                                   268.268   4       1         3.095      √
  55       Astragaloside IV                                  784.98    14      9         1.21       √
  56       Senkyunolide H                                    220.224   4       2         2.314      √
  57       Astragaloside II                                  827.02    15      8         1.91       √
  58       Soyasaponin I                                     943.13    18      11        1.7        *✕*
  59       Methyl tanshinonate                               338.36    5       0         0.93       √
  60       Carnosic acid                                     332.440   4       3         4.603      √
  61       Kaempferol-3-O-glucoside                          448.380   11      7         0.125      *✕*
  62       Hydroxytanshinone IIA                             310.35    4       1         3.24       √
  63       3-Butylidene-7-hydroxyphthalide                   204.225   3       1         2.81       √
  64       Tanshinone II-B                                   310.35    4       1         2.97       √
  65       Senkyunolide A                                    192.258   2       0         3.521      √
  66       Salvianolic acid F                                314.29    6       5         2.33       √
  67       Kumatakenin                                       314.29    6       2         2.98       √
  68       3-n-Butylphthalide                                190.242   2       0         3.483      √
  69       (Z)-Ligustilide^a^                                190.242   2       0         2.927      √
  70       (E)-Ligustilide^a^                                190.242   2       0         2.927      √
  71       Trijuganone B                                     280.32    3       1         3.9        √
  72       Cryptotanshinone^a^                               296.366   3       0         3.83       √
  73       Senkyunolide M                                    278.35    4       1         2.55       √
  74       O-Phthalic anhydride                              148.12    3       0         0.93       √
  75       Chlorogenic acid^a^                               354.311   9       6         −0.453     *✕*
  76       Tanshinone IIA                                    294.350   3       0         4.158      √
  77       Angelicide                                        380.48    4       0         5.73       *✕*
  78       Carthamidin                                       288.255   6       4         1.649      √
  79       Linoleic acid                                     280.45    2       1         6.86       *✕*
  80       Acetyl-11-keto-*β*-boswellic acid                 512.73    5       1         6.39       *✕*
  81       Oleanolic acid                                    456.71    3       2         6.72       *✕*

*Note*. "√" means that component could be absorbed; "*✕*" means that component could not be absorbed.

"a" refers to the component has been verified by standard substance.

###### 

Top 40 Biocarta pathways regulated by NXT (*P* \< 0.01).

  Rank   Pathway                                                                        Count   *P*-value      *q*-value      Gene
  ------ ------------------------------------------------------------------------------ ------- -------------- -------------- -----------------------------------------
  1      NFAT and hypertrophy of the heart (transcription in the broken heart)          6       5.75*E* − 10   3.58*E* − 09   HRAS; GSK3B; MAPK14; FKBP1A; F2; MAP2K1
  2      Phosphoinositides and their downstream targets                                 5       1.39*E* − 09   8.47*E* − 09   GSK3B; PDPK1; BTK; RAB5A; EEA1
  3      Intrinsic Prothrombin Activation Pathway                                       4       8.50*E* − 08   2.82*E* − 07   F10; FGG; F11; F2
  4      Bioactive Peptide Induced Signaling Pathway                                    4       4.08*E* − 07   9.30*E* − 07   HRAS; MAPK14; F2; MAP2K1
  5      BCR Signaling Pathway                                                          4       4.88*E* − 07   1.08*E* − 06   HRAS; MAPK14; BTK; MAP2K1
  6      Estrogen-responsive protein Efp controls cell cycle and breast tumors growth   3       6.40*E* − 07   1.34*E* − 06   CDK2; ESR1; CDK6
  7      Nuclear receptors in lipid metabolism and toxicity                             4       8.02*E* − 07   1.58*E* − 06   CYP2C9; VDR; NR1H3; PPARA
  8      Map kinase inactivation of SMRT corepressor                                    3       1.53*E* − 06   2.48*E* − 06   THRB; MAPK14; MAP2K1
  9      MAP Kinase Signaling Pathway                                                   5       2.09*E* − 06   3.05*E* − 06   HRAS; MAPK10; MAPK14; TGFBR1; MAP2K1
  10     Extrinsic Prothrombin Activation Pathway                                       3       2.99*E* − 06   4.05*E* − 06   F10; FGG; F2
  11     amiPathway                                                                     3       5.17*E* − 06   6.40*E* − 06   F10; FGG; F2
  12     Roles of *β*-arrestin-dependent recruitment of Src kinases in GPCR signaling   3       6.57*E* − 06   7.86*E* − 06   HRAS; HCK; MAP2K1
  13     Aspirin blocks signaling pathway involved in platelet activation               3       8.19*E* − 06   9.49*E* − 06   HRAS; F2; MAP2K1
  14     Insulin Signaling Pathway                                                      3       2.03*E* − 05   2.03*E* − 05   HRAS; INSR; MAP2K1
  15     IL-2 Signaling Pathway                                                         3       2.37*E* − 05   2.29*E* − 05   HRAS; MAP2K1; LCK
  16     Role of ERBB2 in signal transduction and oncology                              3       2.37*E* − 05   2.29*E* − 05   HRAS; ESR1; MAP2K1
  17     Links between Pyk2 and MAP kinases                                             3       2.74*E* − 05   2.45*E* − 05   HRAS; MAPK14; MAP2K1
  18     NF-*κ*B activation by nontypeable Hemophilus influenzae                        3       2.74*E* − 05   2.45*E* − 05   MAPK14; TGFBR1; NR3C1
  19     Influence of Ras and Rho proteins on G1 to S transition                        3       3.14*E* − 05   2.82*E* − 05   HRAS; CDK2; CDK6
  20     fMLP induced chemokine gene expression in HMC-1 cells                          3       3.14*E* − 05   2.82*E* − 05   HRAS; MAPK14; MAP2K1
  21     Growth Hormone Signaling Pathway                                               3       3.14*E* − 05   2.82*E* − 05   HRAS; INSR; MAP2K1
  22     Cell cycle: G1/S checkpoint                                                    3       4.06*E* − 05   3.37*E* − 05   CDK2; GSK3B; CDK6
  23     Fc epsilon receptor I signaling in mast cells                                  3       4.58*E* − 05   3.70*E* − 05   HRAS; BTK; MAP2K1
  24     Signaling of hepatocyte growth factor receptor                                 3       6.40*E* − 05   4.89*E* − 05   HRAS; MET; MAP2K1
  25     p38 MAPK signaling pathway                                                     3       7.85*E* − 05   5.76*E* − 05   HRAS; MAPK14; TGFBR1
  26     Keratinocyte differentiation                                                   3       1.13*E* − 04   7.81*E* − 05   HRAS; MAPK14; MAP2K1
  27     T cell receptor signaling pathway                                              3       1.13*E* − 04   7.81*E* − 05   HRAS; MAP2K1; LCK
  28     TSP-1 induced apoptosis in microvascular endothelial cell                      2       1.46*E* − 04   9.59*E* − 05   CASP3; MAPK14
  29     The role of FYVE-finger proteins in vesicle transport                          2       1.46*E* − 04   9.59*E* − 05   RAB5A; EEA1
  30     Mechanism of gene regulation by peroxisome proliferators via PPARa(alpha)      3       1.82*E* − 04   1.15*E* − 04   HSP90AA1; NR1H3; PPARA
  31     Visceral fat deposits and the metabolic syndrome                               2       1.95*E* − 04   1.21*E* − 04   HSD11B1; NR3C1
  32     RB tumor suppressor/checkpoint signaling in response to DNA damage             2       2.50*E* − 04   1.44*E* − 04   CDK2; CHEK1
  33     Platelet Amyloid Precursor Protein Pathway                                     2       2.50*E* − 04   1.44*E* − 04   F11; F2
  34     Fibrinolysis Pathway                                                           2       3.12*E* − 04   1.77*E* − 04   FGG; F2
  35     Corticosteroids and cardioprotection                                           2       3.12*E* − 04   1.77*E* − 04   HSP90AA1; NR3C1
  36     Phosphorylation of MEK1 by cdk5/p35 downregulates the MAP kinase pathway       2       3.81*E* − 04   2.09*E* − 04   HRAS; MAP2K1
  37     VEGF, hypoxia, and angiogenesis                                                2       5.38*E* − 04   2.79*E* − 04   HRAS; KDR
  38     How progesterone initiates oocyte membrane                                     2       6.27*E* − 04   3.17*E* − 04   HRAS; PGR
  39     IL-3 Signaling Pathway                                                         2       6.27*E* − 04   3.17*E* − 04   HRAS; MAP2K1
  40     Sprouty regulation of tyrosine kinase signals                                  2       6.27*E* − 04   3.17*E* − 04   HRAS; MAP2K1

###### 

The herbs of NXT involved in the top 40 pathways.

  Category                                                                       Pathway                                                                 NXT   RA   RPR   RSM   RAS   RCX   SP   FC   CS   RAB   RC   RM   PT
  ------------------------------------------------------------------------------ ----------------------------------------------------------------------- ----- ---- ----- ----- ----- ----- ---- ---- ---- ----- ---- ---- ----
  Pathway associated with heart diseases and blood vessels                       NFAT and hypertrophy of the heart (transcription in the broken heart)   1     1    1     1     1     1     0    1    1    1     1    1    1
  Intrinsic Prothrombin Activation Pathway                                       1                                                                       0     1    1     1     1     0     1    0    0    0     1    0    
  Extrinsic Prothrombin Activation Pathway                                       1                                                                       0     1    1     1     1     0     1    0    0    0     0    0    
  Aspirin blocks signaling pathway involved in platelet activation               1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  TSP-1 induced apoptosis in microvascular endothelial cell                      1                                                                       1     1    1     1     1     0     1    0    0    0     0    0    
  Platelet Amyloid Precursor Protein Pathway                                     1                                                                       0     0    0     0     1     0     1    0    0    0     1    0    
  Fibrinolysis Pathway                                                           1                                                                       0     1    1     0     1     0     1    0    0    1     0    0    
  Corticosteroids and cardioprotection                                           1                                                                       1     0    1     0     1     0     0    0    0    0     1    0    
  VEGF, hypoxia, and angiogenesis                                                1                                                                       1     1    1     1     1     1     1    1    1    1     1    1    
                                                                                                                                                                                                                           
  Pathway associated with metabolism                                             Nuclear receptors in lipid metabolism and toxicity                      1     1    1     1     0     1     1    1    0    1     0    1    0
  Growth Hormone Signaling Pathway                                               1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Visceral fat deposits and the metabolic syndrome                               1                                                                       1     0    1     1     1     0     0    0    0    0     0    0    
                                                                                                                                                                                                                           
  Pathway associated with immunity                                               *BCR Signaling Pathway*                                                 1     1    1     1     1     1     0    1    1    1     1    1    1
  IL-2 Signaling Pathway                                                         1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  fMLP induced chemokine gene expression in HMC-1 cells                          1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  T Cell Receptor Signaling Pathway                                              1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
                                                                                                                                                                                                                           
  Pathway associated with cell cycle, proliferation, and apoptosis               Phosphoinositides and their downstream targets                          1     0    0     1     0     1     0    1    1    0     0    0    0
  Estrogen-responsive protein Efp controls cell cycle and breast tumors growth   1                                                                       1     1    1     1     1     0     0    1    0    0     0    0    
  Map kinase inactivation of SMRT corepressor                                    1                                                                       1     1    1     1     1     0     1    0    0    0     0    0    
  MAP Kinase Signaling Pathway                                                   1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Roles of *β*-arrestin-dependent recruitment of Src kinases in GPCR signaling   1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Role of ERBB2 in signal transduction and oncology                              1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Links between Pyk2 and MAP kinases                                             1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  NF-*κ*B activation by nontypeable *Hemophilus influenzae*                      1                                                                       1     0    1     1     1     0     1    0    0    0     0    0    
  Influence of Ras and Rho proteins on G1 to S transition                        1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Cell cycle: G1/S checkpoint                                                    1                                                                       1     1    1     1     1     0     0    1    0    0     0    0    
  Fc epsilon receptor I signaling in mast cells                                  1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Signaling of hepatocyte growth factor receptor                                 1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Keratinocyte differentiation                                                   1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  RB tumor Suppressor/checkpoint signaling in response to DNA damage             1                                                                       1     1    1     1     1     0     0    1    0    0     0    0    
  IL-3 Signaling Pathway                                                         1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  Sprouty regulation of tyrosine kinase signals                                  1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
                                                                                                                                                                                                                           
  Other pathways                                                                 Bioactive Peptide Induced Signaling Pathway                             1     1    1     1     1     1     0    1    1    1     1    1    1
  amiPathway                                                                     1                                                                       0     1    1     1     1     0     1    0    0    0     0    0    
  Insulin Signaling Pathway                                                      1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  p38 MAPK Signaling Pathway                                                     1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  The role of FYVE-finger proteins in vesicle transport                          1                                                                       0     0    0     0     0     0     1    0    0    0     0    0    
  Mechanism of gene regulation by peroxisome proliferators via PPAR*α*           1                                                                       1     0    1     0     1     0     0    0    0    0     1    0    
  Phosphorylation of MEK1 by cdk5/p35 downregulates the MAP kinase pathway       1                                                                       1     1    1     1     1     0     1    1    1    1     1    1    
  How progesterone initiates oocyte membrane                                     1                                                                       1     1    1     1     1     1     1    1    1    1     1    1    

*Note*. "1" means that the Chinese herbal medicine acts on the pathway while "0" means it does not. The pathways in each category are sorted by the significant differences in *P* value.

[^1]: Academic Editor: Carmen Mannucci
